Cardunolizumab for advanced vulvar or vaginal cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have vulvar or vaginal cancer that has come back or spread and cannot be cured with standard treatments.
- Your cancer is one of these types: squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (up and about, with only light restrictions).
- You are willing to provide a tissue sample from a past biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This trial tests a drug called tisotumab vedotin for vulvar cancer that has spread or come back. The drug targets a protein on cancer cells to stop them from growing. You may join if you have had only up to 2 prior treatments and are not eligible for curative therapy.
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
This trial tests whether continuing treatment with cemiplimab (an immunotherapy drug) after initial chemotherapy can help keep vulvar cancer from growing, compared to standard supportive care. It is for people whose cancer is stable or improved after their first round of chemotherapy.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
Hear when a new Vulvar and Vaginal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.